'You give me fever!': are health services ready for immune cell engager therapy in advanced solid malignancies?
Loading...
Embargo End Date
ICR Authors
Authors
Pettinger, C
Livings, C
Grochot, R
Furness, A
Lopez, J
Livings, C
Grochot, R
Furness, A
Lopez, J
Document Type
Journal Article
Date
2022-12-01
Date Accepted
2022-12-07
Abstract
Immune cell engager therapeutic strategies using bioengineered molecules to redirect immune cells into tumor are starting to demonstrate promising clinical activity in multiple early phase trials across numerous targets and a range of solid tumor types. These therapies, however, carry the risk of exaggerated cytokine-mediated on-target off-tumor adverse events that require highly specialized inpatient facilities. We report here the Royal Marsden experience of treating patients with advanced solid tumors on early phase immune engager clinical trials in a dedicated inpatient facility, focusing specifically on patterns of cytokine-mediated toxicity seen and proposing a risk-mitigation algorithm for the safe, feasible and scalable delivery of these therapies.
Citation
Journal for ImmunoTherapy of Cancer, 2022, 10 (12), pp. e006073 - e006073
Source Title
Journal for ImmunoTherapy of Cancer
Publisher
BMJ PUBLISHING GROUP
ISSN
eISSN
2051-1426
2051-1426
2051-1426
Collections
Research Team
Skin Unit
Early Phase Drug Develop
Early Phase Drug Develop